The Classification and Cause of Leukodystrophies of Unknown Cause
NCT00001671 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 400
Last updated 2017-07-02
Summary
Leukodystrophy is a disease of the white matter of the brain. White matter is the portion of the brain responsible for conducting electrical impulses from one area of the brain to the other. Insulating cells called myelin cover the brain and nerve cells in the white matter. If myelin becomes damaged electrical information cannot be transferred properly.
Many patients suffering from leukodystrophies do not fit the description of any of the defined types of leukodystrophies and are therefore considered to have a leukodystrophy of unknown cause.
The purpose of this study is to define groups of patients with leukodystrophies and to work toward finding the cause of the disorders. In order to do this, researchers will analyze patients with leukodystrophies of unknown causes. Patients will undergo clinical, neurophysiologic, biochemical, and genetic examinations and tests.
Researchers believe that by studying these patients and their disorders they will be able to better understand the causes of myelin destruction, and eventually lead to effective treatments for these disorders.
Conditions
- Lysosomal Storage Disease
Sponsors & Collaborators
-
National Institute of Neurological Disorders and Stroke (NINDS)
lead NIH
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 1997-09-09
- Completion
- 2008-12-15
Countries
- United States
- France
- Israel
- Netherlands
Study Locations
More Related Trials
-
The Natural History and Pathogenesis of Mucolipidosis Type IV
NCT00015782 ·Status: COMPLETED
-
Determinants of Disease Severity in Amyotrophic Lateral Sclerosis
NCT00004457 ·Status: UNKNOWN
-
Amyotrophic Lateral Sclerosis (ALS) Tissue Donation Program
NCT00716131 ·Status: COMPLETED
-
Mesenchymal Stem Cell Therapy in Multiple System Atrophy
NCT02315027 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Stem Cell Therapy in Limb Girdle Muscular Dystrophy
NCT02050776 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Patient-tailored Genetic/Biomarker/iPSC Combined Approach in ALS - PERMEALS
NCT06917924 ·Status: RECRUITING
-
Analysis of Human ALS Tissues and Registry of ALS Patients
NCT05067179 ·Status: RECRUITING
-
Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial
NCT00035815 ·Status: COMPLETED ·Phase: PHASE3
-
Mechanisms of Cell Death in Spinal Muscular Atrophy
NCT01754441 ·Status: COMPLETED
-
Neurologic Stem Cell Treatment Study
NCT02795052 ·Status: RECRUITING ·Phase: NA
-
Cell-Based Therapy for White Matter Repair in Periventricular Leukomalacia
NCT06985303 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1
-
Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy
NCT05167721 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Transplantation of Autologous Peripheral Blood Mononuclear Cells for Amyotrophic Lateral Sclerosis
NCT03085706 ·Status: COMPLETED ·Phase: NA
-
Exploring Bulbar Function, Speech And Communication Development in SMA Type 1
NCT05954455 ·Status: RECRUITING
-
Study of Two Intrathecal Doses of Autologous Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis
NCT02917681 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Dose Escalation and Safety Study of Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis
NCT01730716 ·Status: UNKNOWN ·Phase: PHASE2
-
sCD163 in ALS Patients
NCT02325375 ·Status: COMPLETED
-
Safety and Tolerability of the Ketogenic Diet in Amyotrophic Lateral Sclerosis (ALS)
NCT01016522 ·Status: TERMINATED ·Phase: PHASE3
-
Measurement and Impact of Physical Impairment in Amyotrophic Lateral Sclerosis: Use of Digital Technologies - A Precision ALS Project
NCT06820008 ·Status: RECRUITING
-
Establishment of a Tissue Bank (Blood, CSF) for the Understanding of Motor Neuron Disease (MND)
NCT01950910 ·Status: TERMINATED
-
Cell Therapy for Motor Neuron Disease/Amyotrophic Lateral Sclerosis
NCT02242071 ·Status: WITHDRAWN ·Phase: PHASE1
-
Interest of Measuring P2X4 Receptors on Blood Monocytes as a Diagnostic Marker in Amyotrophic Lateral Sclerosis: P2X4 as a Diagnostic Biomarker for ALS
NCT07091799 ·Status: RECRUITING ·Phase: NA
-
Clinical Trial Readiness for the Dystroglycanopathies
NCT00313677 ·Status: RECRUITING
-
Bioenergetics and Protein Metabolism in Sporadic Amyotrophic Lateral Sclerosis
NCT02969759 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Autologous Cultured Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in ALS Patients.
NCT01051882 ·Status: COMPLETED ·Phase: PHASE1/PHASE2